

Date: June, 2009.

UNIVERSITY OF KANSAS SCHOOL OF MEDICINE
FACULTY CURRICULUM VITAE

PERSONAL DATA

Name: Diane Lorraine Persons

Department(s): Pathology and Laboratory Medicine

Office Address, Phone, Fax and e-mail

Office: 1213 Clinical Laboratory

Phone: 588-1728

Fax: 588-1777

E-mail: dpersons@kumc.edu

PROFESSIONAL DEVELOPMENT

Undergraduate and Graduate Education:

<u>Years (Inclusive)</u>	<u>Degree</u>	<u>Institution</u>
1970-1974	B.S., Biology	Mankato State University, Mankato MN
1975-1978	M.A., Microbiology	University of Kansas, Lawrence KS
1983-1987	M.D.	University of Kansas Medical Center

Postgraduate Education:

<u>Years (Inclusive)</u>	<u>Area of Study</u>	<u>Institution</u>
1987-1991	Pathology Resident	University of Kansas Medical Center
1991-1993	Research Fellow	Mayo Graduate School
1993-1994	Cytogenetics Fellow	Mayo Graduate School of Medicine

Academic and Other Professional Appointments and Activities:

<u>Month and Year</u>	<u>Position</u>	<u>Institution</u>
July, 1978 – June, 1979	Instructor	Kansas Newman College, Wichita, KS
July, 1979 – June, 1983	Research Associate	St. Francis Hospital, Wichita, KS
September, 1994 - 2000	Assistant Professor	University of Kansas Medical Center
September, 1994 - present	Director, Cytogenetic Laboratory	University of Kansas Medical Center
July, 2000 – June, 2006	Associate Professor	University of Kansas Medical Center
May, 2003 – present	Director, Pathology Residency Program	University of Kansas Medical Center
July, 2006 - present	Professor	University of Kansas Medical Center

Professional Registration/Licensure:

State
Kansas
Minnesota

Professional Certification(s):

<u>Date</u>	<u>Board</u>
1991	American Board of Pathology, Anatomic Pathology
1996	American Board of Medical Genetics, Clinical Cytogenetics

Professional Societies and Affiliations:

<u>Year Joined</u>	<u>Organization</u>
1983	American Medical Association
1987	American Association for the Advancement of Science
1991	American Association for Cancer Research
1992	College of American Pathologists, Fellow
1992	American Society of Human Genetics
1994	Kansas City Society of Pathologists
1995	Association for Molecular Pathology
1996	American College of Medical Genetics, Fellow
1995	Southwest Oncology Group
2000	Association of Clinical Scientists
2003	American Professors of Human and Medical Genetics

Honors/Awards:

<u>Year</u>	
1984	School of Medicine Academic Scholarship
1985	Gouldner Scholarship, University of Kansas Medical School
1985	School of Medicine Academic Scholarship
1987	Alpha Omega Alpha
1987	Janet M. Glasgow Memorial Achievement Citation

National Service (Current):

2000-present	Editorial Board, Annals of Clinical and Laboratory Science
2006-present	Chair, Cytogenetics Resource Committee, College of American Pathologists/ American College of Medical Genetics
2006-present	Member, Molecular Pathology Resource Committee, College of American Pathologists
2009-present	Chair, Molecular Cluster, CAP
2009-present	Member, Council on Scientific Affairs, CAP

National Service (Previous):

1997-2004	Member, Cytogenetics Committee, Southwest Oncology Group
1999-2001	Association for Molecular Pathology, Genetics Nominating Committee
2001-2005	Member, Cytogenetics Resource Committee, College of American Pathologists/ Am College of Medical Genetics
2002	NIH, Subcommittee H (Clinical Trials Cooperative Groups), ad hoc member, review of Children's Oncology Group
2003, 2004	Cancer Fellowship Grant Review Panel, National VFW
2003-2008	Association of Professors of Human and Medical Genetics, representative of University of Kansas School of Medicine
2004 -2008	Co-chair, Cytogenetics Committee, Southwest Oncology Group
2005	NIH, Subcommittee H (Clinical Trials Cooperative Groups) ad hoc member, review of Children's Oncology Group
2005	American Board of Medical Genetics, Item Writer, primary examination, Clinical Cytogenetics

2005	Resident In-Service Exam, Item Writer for Clinical Pathology, ACLPS-ASCP
2007	NIH, Subcommittee H (Clinical Trials Cooperative Groups) ad hoc member, review of Children's Oncology Group

KUMC Service (Current):

2002-present	Member, Kansas Masonic Cancer Research Institute
2003-present	Residency Program Director, Pathology and Laboratory Medicine
2003-present	Chair, Pathology Resident Education Committee
2003-present	School of Medicine, Graduate Medical Education Committee
2004-present	Member, University of Kansas Hospital Laboratory Quality Improvement Team
2006-present	Department of Pathology, Promotion and Tenure Committee

KUMC Service (Previous):

1994 - 2003	Dept of Pathology Medical Student Education Committee
1994 - 2005	Dept of Pathology Graduate Studies and Research Committee
1996	Clinical Laboratory Steering Committee
1996	Laboratory Network Planning Committee
1996 - 1997	University of Kansas Medical Alumni Board of Directors Co-Chair 10 year reunion Class of 1987
1998	KUMC Faculty Review Task Force
1998 - 2002	Dept of Pathology Finance Committee
1998 - 2002	Graduate School, Graduate Travel Committee
1999 - 2003	Medical Student Course Evaluation Task Force
1999 - 2001	Residency Task Force
1999 - 2001	Research Task Force
2000 - 2001	Faculty Incentive Task Force
2000 - 2001	Surgical Pathology Task Force
2001 - 2004	Chair, University of Kansas Hospital Laboratory Quality Improvement Team
2002-2003	Genetics Curriculum Subcommittee, School of Medicine
2002	Chair, Department of Pathology and Laboratory Medicine Faculty Research Fund Task Force
2005-2007	School of Medicine, Nominating Committee
2005-2008	School of Medicine, Academic Committee
2006-2008	School of Medicine, Graduate Medical Education, Competencies Subcommittee

RESEARCH FUNDING**Current Funding:**

Co- PIs: Yu-Ping Wang and Diane L. Persons
 Title of Grant: Rapid and Accurate Detection of Chromosomal Abnormalities Via Multi-color Imaging
 Funding Source: Kansas City Area Life Sciences Institute
 Period of Support: 10/01/08 – 09/30/09

Principal Investigator: Diane L. Persons
 Title of Grant: Cisplatin-enhancing Agents – Development of Novel Compounds
 Funding Source: KUMC Research Institute
 Period of Support: 04/04/08 – 04/03/09

Previous Support:

Title of Grant: Southwest Oncology Group, NIH U10CA32102-25
 Position: Co-Chair, Cytogenetics Committee
 Funding Source: Southwest Oncology Group, Subcontract
 Period of Support: 04/01/04 – 3/31/08

Principal Investigator: Diane L. Persons
 Title of Grant: Cisplatin-enhancing Agents – Development of Novel Compounds
 Funding Source: Kansas Masonic Cancer Research Institute
 Period of Support: 12/01/05 – 12/31/06

Principal Investigator: Diane L. Persons
 Title of Grant: Regulation of p53 by cisplatin induced ERK activity
 Funding Source: American Cancer Society
 Period of Support: 01/01/01 – 12/31/05

Principal Investigator: Diane L. Persons
 Title of Grant: A longitudinal Continuation Study of the Vysis UroVysion Bladder Cancer Test in Patients Symptomatic for Bladder Cancer
 Funding Source: Vysis, Inc.
 Period of Support: 09/01/04 – 06/30/06

Principal Investigator: Diane L. Persons
 Title of Grant: A Validation Study of the ThinPrep Urocyte Collection and Slide Preparation System with UroVysion
 Funding Source: Vysis, Inc.
 Period of Support: 01/01/05 – 12/31/05

Principal Investigator: Joan Knoll and Diane L. Persons, Co-PIs
 Title of Grant: Sequence definition of chromosome 9;22 rearrangements in leukemia
 Funding Source: Hall Family Foundation Joint Research Grant
 Period of Support: 03/01/01 – 09/31/04

Principal Investigator: Diane L. Persons

Title of Grant: Gene copy number alterations, as detected by FISH, as prognostic markers for progression of malignant melanoma.
 Funding Source: Southwest Oncology Group Developmental Award, NIH 5U10CA32102
 Period of Support: 01/01/02 – 12/31/03

Principal Investigator: Diane L. Persons
 Title of Grant: A prospective study of the UroVysion Bladder Cancer Recurrence Test in patients symptomatic for bladder cancer
 Funding Source: Vysis, Inc.
 Period of Support: 07/01/02 – 06/30/04

Principal Investigator: Gunda Georg, Program Project
 Diane L. Persons, Principal Investigator of First Award
 Title of Grant: Center for Cancer Experimental Therapeutics (COBRE)
 First Award Title - PI3K-related kinases and the cisplatin response
 Funding Source: NIH 1 P20 RR15563-01
 Period of Support: 10/01/00 – 9/31/05, First Award – 02/01/01 – 01/31/02

Principal Investigator: Diane L. Persons
 Title of Grant: Reproducibility and Specificity of Bladder Cancer FISH Assay
 Funding Source: Vysis, Inc.
 Period of Support: 3/01/00 – 02/31/01

Principal Investigator: Diane L. Persons
 Title of Grant: Clinical Cytogenetics Development
 Funding Source: Patton Trust, KUMC Endowment
 Period of Support: 10/01/97 – 09/30/01

Principal Investigator: Stephen W. Russell
 Investigators: PI of Project #3, Diane L. Persons
 Title of Grant: Institutional Development Award (IDeA), Sustained Development of Clinician-Researchers in Kansas
 Funding Source: NIH, KTEC
 Period of Support: 10/01/96 – 09/30/00

Principal Investigator: Diane L. Persons
 Title of Grant: HER-2/neu Amplification in Advanced Stage Melanoma
 Funding Source: Southwest Oncology Group and Vysis, Inc.
 Period of Support: 02/01/99 – 1/31/00

Principal Investigator: Diane L. Persons
 Title of Grant: HER-2/neu Amplification in Breast Carcinoma
 Funding Source: Vysis, Inc.
 Period of Support: 05/01/95 – 04/30/99

Principal Investigator: Diane L. Persons
 Title of Grant: HER-2/neu, TNF-alpha and Chemoresistance in Ovarian carcinoma
 Funding Source: Kansas Cancer Institute, Seed Grant
 Period of Support: 01/01/96 – 09/30/96

REFEREED JOURNAL ARTICLES

1. Persons, D.L. and Shankel, D.M. Effect of antimutagens on prophage induction in E. coli lysogenic for lambda. *Environmental Mutagenesis* 5:59-71, 1983.
2. Persons, D.L., Moore, J.A. and Fishback, J.L. Comparison of polymerase chain reaction, DNA hybridization, and histology with viral culture to detect cytomegalovirus in immunosuppressed patients. *Modern Pathology* 4:149-153, 1991.
3. Kerley, S.W., Persons, D.L. and Fishback, J.L. Human papilloma virus and carcinoma of the urinary bladder. *Modern Pathology* 4:316-319, 1991.
4. Persons, D.L., Bridge J.A. and Neff, J.R. Cytogenetic analysis of two sacral chordomas. *Cancer Genetics and Cytogenetics* 56:197-201, 1991.
5. Bridge, J.A., Persons, D.L., Neff J.R. and Bhatia, P. Clonal karyotypic aberrations in enchondromas. *Cancer Detection and Prevention* 16:215-219, 1992.
6. Persons, D.L., Hartmann, L.C., Herath, J.F., Borell, T.J., Cliby, W.A., Keeney, G.L., and Jenkins, R.B. Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas. *The American Journal of Pathology* 142:733-742, 1993.
7. Persons, D.L., Gibney, D.J., Katzmann, J.A., Lieber, M.M., Farrow, G.M. and Jenkins, R.B. Use of fluorescence *in situ* hybridization for deoxyribonucleic acid ploidy analysis of prostate carcinoma. *The Journal of Urology* 150:120-125, 1993.
8. Jenkins, R.B., Bartelt, D., Stalberger, P., Persons, D.L., Dahl, R., Keeney, G. and Hartmann, L.C. Cytogenetic studies of epithelial ovarian carcinomas. *Cancer Genetics and Cytogenetics* 71:76-86, 1993.
9. Persons, D.L., Takai, K., Gibney, D.J., Katzmann, J.A., Lieber, M.M. and Jenkins, R.B. Comparison of fluorescence *in situ* hybridization with flow cytometry and static image analysis in ploidy analysis in paraffin-embedded prostate adenocarcinoma. *Human Pathology*, 25:678-683,1994.
10. Brown, J.A., Alcaraz, A., Takahashi, S., Persons, D.L., Lieber, M.M., and Jenkins, R.B. Chromosomal aneusomies by fluorescence *in situ* hybridization analysis in clinically localized prostate carcinoma. *The Journal of Urology*, 152:1157-1162,1994.
11. Persons, D.L., Hartmann, L.C., Herath, J., F., Keeney, G.L., and Jenkins, R.B. Fluorescence *in situ* hybridization analysis of trisomy 12 in ovarian tumors. *American Journal of Clinical Pathology*, 102:775-779, 1994.
12. Jalal, S.M., Lindor, N.M., Persons, D.L., and Dewald, G.W. A form of 15q proximal duplication appears to be a normal euchromatic variant. *American Journal of Medical Genetics*, 52:495-497,1994.
13. Persons, D.L., Robertson, R.A., Hsu, P.H., Seelig, S.A., Borell, T.J., Hartmann, L.C and Jenkins, R.B. Chromosome-specific aneuploidy in carcinomas of the breast. *Clinical Cancer Research*, 2:883-888, 1996.
14. Brown, J.A., Takahashi, S., Alcaraz, A, Borell, T.J., Anderl, K.L., Quian, J., Persons, D.L., Bostwick, D.G., Lieber, M.M., and Jenkins, R.B. Fluorescence *in situ* hybridization analysis of renal oncocytoma reveals frequent loss of chromosomes Y and 1. *The Journal of Urology*, 156:31-35, 1996.

15. Tawfik, O., Austenfeld, M. and Persons, D. Multicentric renal angiomyolipoma in association with pulmonary lymphangiomyomatosis: Case report, with histologic, immunochemical and DNA content analysis. *Urology*, 48:476-480, 1996.
16. Persons, D.L., Borelli, K.A., Hsu, P. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence *in situ* hybridization. *Modern Pathology*, 10:720-727, 1997.
17. Banerjee, S.K., Weston, A.P., Persons, D.L., Campbell, D.R. Nonrandom loss of chromosome 3 during transition from Helicobacter Pylori associated gastric MALT to B-cell MALT lymphoma revealed by fluorescence *in situ* hybridization. *The Cancer Letter*, 121:83-90, 1997.
18. Persons, D.L., Croughan W.S., Borelli, K.A and Cherian, R. Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions. *Cancer Genetics and Cytogenetics*, 106:11-17, 1998.
19. Banerjee, S.K., Weston, A.P., Persons, D.L., Campbell, D.R. Quick-FISH: A rapid fluorescence *in situ* hybridization technique for molecular cytogenetic analysis. *Biotechniques*, 24:826-830, 1998.
20. Posey, Y., Valdivia, M., Persons, D. L., Ally, S., Pantazis, C. and Smith, S.D. Lipoblastoma presenting as a mesenteric mass in an infant. *Journal of Pediatric Hematology and Oncology*, 20(6):580-582, 1998.
21. Yazlovitskaya, E.M., Pelling, J.C. and Persons, D.L. Association of apoptosis with the inhibition of extracellular signal-regulated protein kinase activity in the tumor necrosis factor α -resistant ovarian carcinoma cell line UCI 101. *Molecular Carcinogenesis*, 25:14-20, 1999.
22. Persons, D.L., Yazlovitskaya, E.M., Cui, W. and Pelling, J.C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: Inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. *Clinical Cancer Research*, 5:1007-1014, 1999.
23. Persons, D.L., Bui, M.M., Yung, J-F., Lowery, M.C., Mark, H.F.L., Wong, E.Y., Birkmeier, J.M., Yang, S.J., and Masood, S. Fluorescence *in-situ* hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: A multicenter portability study. *Annals Clinical and Laboratory Science*, 30:41-48, 2000.
24. Roby, K.F., Taylor, C.C., Cheng, Y., Pace, J., Tawfik, O., Persons, D.L., Smith, P.G., and Terranova, P.F. Development of a syngeneic murine model for ovarian cancer. *Carcinogenesis*, 21:585-591, 2000.
25. Persons, D.L., Arber D.A., Sosman, J.A., Borelli, K.A., Slovak, M.L. Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma. *Anticancer Research*, 20:1965-1968, 2000.
26. Persons, D.L., Yazlovitskaya, E.M., and Pelling, J.C. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. *The Journal of Biological Chemistry*, 275:35778-35785, 2000.
27. Cui, W., Yazlovitskaya, E.M., Mayo, M.S., Pelling, J.C., and Persons, D.L. Cisplatin-induced response of c-Jun-N-terminal 1 and extracellular signal-regulated protein kinase 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. *Molecular Carcinogenesis*, 29: 219-228, 2000.
28. Oweity, T., Persons, D., and Tawfik, O. Carcinoma of the prostatic urethra: Report of a case following radiation treatment for prostatic adenocarcinoma. *Journal of Urologic Pathology*, 12:199-212, 2000.
29. Yazlovitskaya, E.M., DeHaan, R.D., and Persons, D.L. p53 and p21WAF-1 protein accumulation in cisplatin-sensitive and -resistant ovarian carcinoma cell lines. *Biochemical and Biophysical Research Communications*, 283:732-737, 2001.

30. DeHaan, R.D., Yazlovitskaya, and Persons, D.L. ERK modulation of expression of p53-regulated genes during cisplatin treatment. *Cancer Chemotherapy and Pharmacology*, 48 (5): 383-388, 2001.
31. List, A.F., Kopecky K.J., Willman, C.L., Dorr, R., Persons, D.L., Chen, I-M., Karanes, C., Slovak, M.L., Hynes, H.E., Appelbaum, F., and the Southwest Oncology Group (SWOG). Benefit of Cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia. *Blood*, 98:3212-3220, 2001.
32. Tubbs, R.R., Colley, L., Hsi, E.D., Linden, M.D., Pettigrew, N.M., Rickert, R.R., Said, J.W., Bayer-Garner, I.B., Nagle, R.B., Brothman, A.R., Persons, D.L., Habegger Vance, G., Mascarello, J.T., Roa, K.W., Herrmann, M., DeWald, G. and Park, J.P. Clinical laboratory assays for HER-2/neu amplification and overexpression: Quality assurance, standardization, and proficiency testing. *Archives of Pathology and Laboratory Medicine*, 126:803-808, 2002.
33. Slovak, M.L., Zhang, F., Tcheurekdjian, L., Bobadilla, D., Bedell, V., Arber, D.A., Persons, D.L., Sosman, J.A., Murata-Collins, J.L. Targeting multiple genetic aberrations in isolated tumor cells by Spectral Fluorescence In-Situ Hybridization (S-FISH). *Cancer Detection and Prevention*, 26:171-179, 2002.
34. Ladesich, J., Damajov, I., Persons, D., Jewell, W., Arthur, T., Rogona, J., and Davoren, B. Complex karyotype in low grade phyllodes tumor of the breast. *Cancer Genet Cytogenet*, 132:149-151, 2002.
35. Mascarello, J.T., Brothman, A.R., Keri Davison, K., Dewald, G.W., Herrman, M., McCandless, Jonathan P. Park, J.P., Persons, D.L., Rao, K.W., Schneider, N.R., Vance, G.H., Cooley, L.D. Proficiency Testing for Laboratories Performing Fluorescence *in Situ* Hybridization with Chromosome-Specific DNA Probes. *Archives of Pathology and Laboratory Medicine*, 126:1458-1462, 2002.
36. Yazlovitskaya EM and Persons DL. Activation of ATR by cisplatin and affect on G2/M cell cycle components. *Anticancer Research*, 23:2275-2280, 2003.
37. Mascarello, J.T., Cooley, L.D., Dewald, G.W., Brothman, A.R., Herrman, M., Park, J.P., Persons, D.L., Rao, K.W., Schneider, N.R., Davison, K., and Vance, G.H. Problems with ISCN FISH nomenclature make it not practical for use in clinical test reports or cytogenetic databases. *Genetics in Medicine*, 5:370-377, 2003.
38. Imkie, M., Davis, M.K., Persons, D.L., and Cunningham, M.T. Biphasic acute myeloid leukemia with near-tetraploidy and immunophenotypic transformation. *Archives of Pathology and Laboratory Medicine*, 128:448-451, 2004.
39. Chu, W., Chapman, J., Persons, D.L., and Fan, F. Twin pregnancy with partial hydridiform mole and coexisting fetus. *Archives of Pathology and Laboratory Medicine*, 128:1305-1306, 2004.
40. Namiq, A.L., Persons, D.L., Piehler, J, and Damjanov, I. Monosomy 22 and trisomy 14 in a granulosa tumor metastatic to the lung 20 years after removal of the primary tumor. *Cancer Genetics and Cytogenetics*. 159: 192-193, 2005.
41. Dressler, L.G., Berry, D.A., Broadwater, G., Cowan, D., Cox, K., Griffith, S., Miller, Ashley, Tse, J., Novotny, D., Persons, D.L., Barcos, M., I. Henderson, I.C., Liu, E., Thor, A., Budman, D., Muss, H., Norton, L. and Hayes, D.F. Comparison of HER2 Status by Fluorescence in Situ Hybridization (FISH) and Immunohistochemistry (IHC) to predict Benefit from Dose Escalation of Adjuvant Doxorubicin-based Therapy in Node Positive Breast Cancer Patients. *The Journal of Clinical Oncology*, 23: 4287-4297, 2005.

42. Tawfik, O.W., Kimler, B.F., Davis, M., Donahue, J.K, Persons, D.L., Fan, F., Hagemeister, S., Thomas, P., Connor, C., Jewell, W., and Fabian, C.J. Comparison of immunohistochemistry (IHC) by automated cellular imaging system (ACIS) vs fluorescence in situ hybridization (FISH) in the evaluation of Her-2/neu expression in primary breast carcinoma. *Histopathology*, 48:258-267, 2006.
43. Persons, D.L., Tubbs, R.R., Cooley, L.D., Dewald, G.W., Dowling, P.K., Du, E., Mascarello, J.T., Rao, K.W., Wilson, K.S., Wolff, D.J. and Vance, G.H. HER2 Fluorescence *in situ* hybridization (FISH): Results from the Survey Program of the College of American Pathologists (CAP). *Archives of Pathology and Laboratory Medicine*, 130:325-331, 2006.
44. Stasik, CJ, Ganguly, S., Hagemeister, S, Cunningham, M, and Persons, DL. Infant Acute Lymphoblastic Leukemia with t(11;16)(q23;p13.3) and Lineage Switch into Acute Monoblastic Leukemia. *Cancer Genetics and Cytogenetics*, 168:146-149, 2006.
45. Sarosdy, M.F., Kahn, P.R., Ziffer, M.D., Love, W.R., Barkin, J., Abara, E.O., Jansz, K., Bridge, J.A., Johannson, S.L., Persons, D.L., and Gibson, J. Use of the UroVysion Multi-target Fluorescent In-situ Hybridization Assay to diagnose bladder cancer in patients with hematuria. *Journal of Urology*, 176:44-47, 2006.
46. Schimke, R.N., Collins, D.L., Persons, D. Epithelioid Sarcoma in a Patient with a Ring Chromosome 22. *Proceedings of the Greenwood Genetic Center*, 25:160-161, 2006.
47. Brothman, A., Schneider, N., Saikevych, I., Colley, L., Butler, M., Patile, S., Mascarello, J., Roa, K., Dewald, G., Park, J., Persons, D.L., Wolff, D., Vance, G. Cytogenetic Heteromorphisms: G-band regions we have pondered for years. *Archives of Pathology and Laboratory Medicine*, 130:947-949, 2006.
48. Dennis, K.L., Wallentine, S.L., Vanveldhuizen, P.J., Persons, D.L., Mathur, S.C. Biclinal Post-Transplant B-cell Lymphoma: report of a case with two distinct cell populations- XX,t(14;18) and XY,t(11;14). *Cancer Genetics and Cytogenetics* 173:150-153, 2007.
49. Wolman, S.R., Goldman, B., Slovak, M.L., Tangen, C., Persons, D.L., Wood, D. Aneusomy for Detection of Bladder Cancer Recurrence: A Southwest Oncology Group Study. *Cancer Genetics and Cytogenetics* 176:22-27, 2007.
50. Patel, V.M., Raghuvver, T.S., Persons, D.L., Myers, S.A. Trisomy 4q syndrome phenotypically similar to trisomy 18. *Internet Journal of Pediatrics & Neonatology*, 7:2, 2007.
51. Moore, S.R., Persons, D.L., Sosman, J.A., Bobadilla, D., Bedell, V., Smith, D.D., Wolman, S.R., Tuthill, R.T., Moon, J., Sondak, V.K., and Slovak, M.L. Detection of copy number alterations in metastatic melanoma by both a panel of 16 DNA FISH Probes and array comparative genomic hybridization: a Southwest Oncology Group Study (S9431). *Clinical Cancer Research*, 14:2927-2935, 2008.
52. Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB, Persons DL, Tubbs RR, Hammond MEH. Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and Guidelines, *Arch Pathol Lab Med*, 133:611-612, 2009.
53. Zhang D, Persons DL, McGuirk J, Ganguly S. Histiocytic/dendritic cell sarcoma arising from follicular lymphoma involving the bone: A case report and review of literature. *International Journal of Hematology*, 89:529-532, 2009.

BOOK/BOOK CHAPTERS

1. Bridge, J.A. and Persons, D.L. "Cytogenetics", pp 271-283. In: *Laboratory Test Handbook*, D.S. Jacobs (ed.), Lexicomp, Inc., Hudson, OH, 1996.
2. Persons, D.L., contributing author, *Concise Laboratory Test Handbook*, Editors, Jacobs, D.S. and Grady, H.J., Lexicomp, Inc., Hudson, OH, 1996.
3. Persons, D.L., "Cytogenetics" pp 359-368, In: *Laboratory Test Handbook*, D.S. Jacobs (ed.), Lexicomp, Inc., Hudson, OH, 2001.
4. Persons, D.L., DeMott, W.R., and Jacobs, D.S. "Molecular Oncology" pp 719-730, In: *Laboratory Test Handbook*, D.S. Jacobs (ed.), Lexicomp, Inc., Hudson, OH, 2001.
5. Jacobs, D.S, DeMott, W.R., Oxley, D.K., Garg, U., Horvat, R., Persons, D.L., and Van Cott, E.M., *Concise Laboratory Test Handbook*, Lexicomp, Inc., Hudson, OH, 2001.

INVITED OR NON-PEER-REVIEWED ARTICLES/REVIEWS/PUBLICATIONS

1. Persons, D.L., *Cancer Cytogenetics*, Editors - Heim, S., Mitelman, F., *Modern Pathology* 9:204, 1996. (Book Review)
2. Persons, D.L., *Human Cytogenetics: Essential Data*, Editors - Rooney, D.E, Czepulkowski, B.H., *Modern Pathology* 9:646, 1996. (Book Review)
3. Persons, D.L., *Advances in Cytogenetics*. Jayhawk Kidtalk, Summer, 1998.
4. Persons, D.L., *The Principles of Clinical Cytogenetics*, Editors - Gerson, S.L. And Keagle, M.B., *Modern Pathology* 12:902, 1999. (Book Review)
5. Persons, D.L., HER-2/neu Fluorescence In Situ Hybridization (FISH) Proficiency Test, Participant Summary Report, CYH-A Survey, College of American Pathologists and American College of Medical Genetics, December 2002.
6. Persons, D.L., Cytogenetics, CYC 2002 Proficiency Test, Participant Summary Report, College of American Pathologists and American College of Medical Genetics, February 2003.
7. McLaughlin, L. and Persons, D.L.. *Atlas of Human Chromosome Heteromorphisms*, Editors - Wyandt, H.E. and Tonk, V.S, *Modern Pathology* 17:204, 2004. (Book Review)
8. Persons, D.L., HER-2/neu Fluorescence In Situ Hybridization (FISH) Proficiency Test, Participant Summary Report, CYH-A Survey, College of American Pathologists and American College of Medical Genetics, November, 2004.

ABSTRACTS

1. Persons, D.L. and Shankel, D.M. Effect of antimutagens on prophage induction in E. coli lysogenic for lambda. Annual meeting American Society of Microbiology. May 1978.
2. Persons, D.L., Sandberg, A.A., Bridge, J.A. Cytogenetic abnormalities of enchondromas. Fourth International Workshop on Chromosomes in Solid Tumors, February 1991.

3. Persons, D.L., Herath, J.F., Borell, T.J., Dewald, G.W., Hartmann, L.C. and Jenkins, R.B. Interphase Molecular Cytogenetic Analysis of Ovarian Carcinomas. International Symposium on Molecular Cytogenetics. February 1992.
4. Cliby, W.A., Ritland, S.R., Hartmann, L.C., Persons, D.L., Podratz, K.C. and Jenkins, R.B. Frequent allelic loss in epithelial ovarian cancers mapped to chromosome arms 6p, 6q, 11p, 13q, 17p and 17q. American Association for Cancer Research. May 1992.
5. Jenkins, R.B., Takai, K., Gibney, D.J., Katzmann, J.A., Lieber, M.M. and Persons, D.L. The use of fluorescent *in situ* hybridization for ploidy analysis in prostatic adenocarcinoma. Fifth International Workshop on Chromosomes in Solid Tumors, January 1993.
6. Persons, D.L., Takai, K., Lieber, M.M. and Jenkins, R.B. The use of fluorescence *in situ* hybridization (FISH) for ploidy analysis in paraffin-embedded prostatic adenocarcinoma. Genitourinary Oncology Conference: The Clinical Implications of Prostate Cancer Biology. February 1993.
7. Persons, D.L., Borell, T.J., Hartmann, L.C., Herath, J.F. and Jenkins, R.B. Interphase cytogenetics in breast carcinomas. American Association of Cancer Research. May 1993.
8. Persons, D.L., Gibney, D.J., Katzmann, J.A., Lieber, M.M., Farrow, G.M., and Jenkins, R.B. The use of fluorescence *in situ* hybridization for DNA ploidy analysis in prostatic adenocarcinoma. American Urological Association Annual Meeting. May 1993.
9. Persons, D.L., Hartmann, L.C., Keeney, G.L. and Jenkins, R.B. Trisomy 12 detected by fluorescence *in situ* hybridization in ovarian tumors. American Society of Human Genetics Annual Meeting, October 1993.
10. Brown, J.A., Alcaraz, A., Takahashi, S., Persons, D.L., Lieber, M.M., and Jenkins, R.B. Chromosomal aneusomies by fluorescence *in situ* hybridization (FISH) analysis in clinically localized prostate carcinoma. American Urological Association Annual Meeting. May 1994.
11. French, A.W., Persons, D.L., Herath, S.E., Jenkins, R.B. And Thibodeau, S.N. Chromosome-specific aneusomy in colorectal carcinoma. American Society of Human Genetics Annual Meeting, October 1994.
12. Shan, A.L., Wick, M.J., Persons, D.L., and Thibodeau, S.N. Microsatellite instability in prostate cancer. The American Society of Human Genetics Annual Meeting, October 1994.
13. Hanson, C.A., Persons, D.L., Kurtin, P.J., and Dewald, G.W. t(5;12)(q31;p13): A distinct chronic myeloproliferative disorder (CMPD) with marrow eosinophilia. International Academy of Pathology Annual Meeting, September 1995.
14. Takahashi, S., Alcaraz, A., Brown, J.A., Borell, T.J., Herath, J.F., Persons, D.L., Bergstrahl, E.J., Lieber, M.M., and Jenkins, R.B. Aneusomies detected by fluorescence *in situ* hybridization (FISH) are prognostic for pathologic stage C prostate cancer patients. American Urological Association Annual Meeting. May 1995.
15. Persons, D.L., Borelli, K.A., and Hsu, P.H. HER2/neu amplification and overexpression in breast carcinoma: detection by fluorescence *in situ* hybridization compared to immunohistochemistry. American Association for Cancer Research Annual Meeting, May 1996.
16. Becker, T.A., Olney, A.H., Sanger, W.G, Ardinger, H.H. and Persons, D.L. Two translocation families with identical rare del(8p) and dup(12p): The evolving phenotype and early overgrowth. American Society of Human Genetics Annual Meeting, October 1996.

17. Persons, D.L., Croughan W.S., Borelli, K.A and Cherian, R. Interphase cytogenetics in esophageal carcinoma. American Society of Human Genetics Annual Meeting, October, 1996.
18. Freeman , E., Tawfik, O. and Persons, D.L. HER-2/neu amplification in endometrial carcinoma. American Society of Clinical Pathology/College of American Pathologist, November 1996.
19. Ardinger, H.H., Ardinger, R.H., Goertz, K.K., Persons, D.L., and Weatherstone, K.B. Concordance of heart defects in monozygotic twins with del 22q11 may be related to originally equal division of the inner cell mass. The David Smith Annual Symposium, February 1997.
20. Ardinger, H.H. and Persons, D.L. Segmental bicolored irides as a sign of deletion 13q22. The David Smith Annual Symposium, February 1997.
21. Levitch, L.M., Zimmer, J.G., Gunter, J., Burloaw, J., Arthur, T., Hankins, L., Ardinger, R., and Persons, D.L. Monozygotic twins with chromosome 22q11 deletion and concordant heart defects. American Society of Human Genetics Annual Meeting, October 1997.
22. Yazlovitskaya, E.M., Pelling, J.C. and Persons, D.L. ERK activity modulates TNF- -induced growth inhibition: comparison of two ovarian carcinoma cell lines. American Association for Cancer Research Annual Meeting, May 1998.
23. Levitch, L., Burlbaw, J., Persons, D., Ragona,J., Davoren, B., Weatherstone, K., Ardinger, H., and Ashewll, R. Prenatal and postnatal manifestations of 46,XX,der(4)dup(4)(q35.2q32.2t(4;18) (q32;q12.2). American Society of Human Genetics Annual Meeting, October 1998.
24. Yazlovitskaya, E.M., Cui, W., Pelling, J.C., and Persons, D.L. Cisplatin induction of MAP kinases in ovarian carcinoma cell lines: Inhibition of ERK sensitizes cells to cisplatin. American Association for Cancer Research Annual Meeting, April 1999.
25. Cui, W., Yazlovitskaya, E.M., Pelling, J.C., and Persons, D.L. Correlation between cisplatin sensitivity and induction of MAP kinases in ovarian carcinoma. American Association for Cancer Research Annual Meeting, April 1999.
26. Persons, D.L., Bui, M.M., Yung, J-F., Lowery, M.C., Mark, H.F.L., Wong, E.Y., Birkmeier, J.M., Yang, S-J., and Masood, S. Fluorescence *in-situ* hybridization (FISH) for detection of HER-2/*neu* amplification in breast cancer: A multicenter portability study. American Association for Cancer Research Annual Meeting, April 1999.
27. Dressler, L.G., Berry, D., Liu, E., Cowan, D., Broadwater, G., Tse, J., Cox-Jones, K., Griffith, S., Miller, A., Persons, D. L., Novotny, D., Muss, H., Norton, L., and Hayes, D. Amplification of erbB2 by Fluorescent *In Situ* Hybridization (FISH): An alternate method to predict outcome following dose-escalated CAF in Stage II, node positive breast cancer patients. A Cancer and Leukemia Group B (CALGB) Study. American Society of Clinical Oncology Annual Meeting, March 1999.
28. Ardinger, H.H, Persons, D.L., Lutz, R. , Beattie, M.A. Hypotonia and developmental delay: Hallmarks of a terminal deletion of chromosome 2q. American Society of Human Genetics Annual Meeting, October 1999.
29. Weston, A.P., Banerjee, S.K., Persons, D.L., Cherian, R., Sharma, P. P53 positivity in low-grade dysplasia (LGD) in Barrett's esophagus: Marker predictive of progression to cancer or multifocal high-grade dysplasia (mHGD). American College of Gastroenterology 64th Annual Scientific Meeting, October 1999.

30. Persons, D.L., Cansler, M., Runnebaun, S., Collins, J., Borelli, K., and Tawfik, O. Comparison of fluorescence in situ hybridization and immunohistochemistry for evaluation of HER-2/neu in breast carcinoma. Association for Molecular Pathology, November, 1999.
31. Yazlovitskaya, E.M., DeHaan, R.D., Pelling, J.C., and Persons, D.L. p53 and p21WAF-1 protein accumulation in cisplatin-sensitive and –resistant ovarian carcinoma cell lines. American Association for Cancer Research Annual Meeting, April 2000.
32. Persons, D.L., Yazlovitskaya, E.M., and Pelling, J.C. ERK activity and regulation of p53 protein accumulation in ovarian carcinoma cell line A2780 during exposure to cisplatin. American Association for Cancer Research Annual Meeting, April 2000.
33. DeHaan R.D. and Persons, D.L. The role of cisplatin-induced ERK activity in the expression of p53 regulated genes. Student Research Forum, University of Kansas Medical Center, April 2000.
34. Persons, D.L., Ardinger, H.H., Arthur, T.M., Davoren, B.D., Hankins, L.D., Ragona, J.E. Duplication of the proximal portion of chromosome 5p. American Society of Human Genetics Annual Meeting, October 2000.
35. Persons, D.L. and Yazlovitskaya, E.M. Extracellular signal-regulated kinase dependent phosphorylation of p53 at serine 15 during cisplatin treatment. Molecular Biology and New Therapeutic Strategies: Cancer Research in the 21st Century. 5th Joint Conference of the American Association of Cancer Research and the Japanese Cancer Association, February 2001.
36. Yazlovitskaya, E.M. and Persons, D.L. Phosphorylation of p53 at serine residues in ovarian carcinoma cell line A2780 during cisplatin treatment. Am. Association for Cancer Research Annual Meeting, March 2001.
37. Persons, D.L. and Yazlovitskaya, E.M. Extracellular signal-regulated kinase dependent phosphorylation of p53 at serine 15 during cisplatin treatment. KUMRI Alliance Spring Research Conference, April 2001.
38. Yazlovitskaya, E.M., Nudson, W., and Persons, D.L. Regulation of Mdm2 and p53 interaction by ERK during cisplatin exposure. Keystone Conference on Cancer Pathology, July 2001.
38. Tubbs, R.R., Colley, L., Roche, P.C., Hsi, E.D., Linden, M.D., Pettigrew, N.M., Rickert, R.R., Said, J.W., Bayer-Garner, I.B., Nagle, R.B., Brothman, A.R., Persons, D.L., Habegger Vance, G., Mascarello, J.T., Roa, K.W., Herrmann, M., DeWald, G. and Park, J.P. (CAP Cell Markers Committee and ACMG/CAP Cytogenetics Committee). Relative performance of immunohistochemistry and FISH assays for HER-2/neu gene amplification/overexpression: Paired specimen results from the Cell Markers and Cytogenetics Committees of the College of American Pathologists (CAP), Unites States and Canadian Association of Pathology, Annual Meeting, February 2002.
39. Slovak. M.L., Zhang, F., Tcheurekdjian, L., Bobadilla, D., Bedell, V., Arber, D.A., Persons, D.L., Sosman, J.A., Murata-Collins, J.L. Targeting multiple genetic aberrations in isolated tumor cells by Spectral Fluorescence In Situ Hybridization (S-FISH). International Society for Preventive Oncology, Annual Meeting, February 2002.
40. Yazlovitskaya, E.M., Nudson, W., and Persons, D.L. Regulation of Mdm2 by ERK during cisplatin exposure. American Association for Cancer Research Annual Meeting, April 2002.
41. Yazlovitskaya, E.M. and Persons, D.L. Activation of the ATR pathway by cisplatin in A2780 cells, Center of Biological Research Excellence annual Meeting, May 2002.

42. Li, Y., Battaglia, T., Davis, M., Hankins, L., Hagemester, S., Arthur, T., Tawfik, O. and Persons D.L. Comparison of Fluorescence *In situ* Hybridization and Immunohistochemistry for HER-2/*neu* Detection in Breast Carcinoma. American Association of Clinical Pathologists/College of American Pathologists Annual Meeting, October 2002.
43. Tubbs, R., Nagle, R., DeLellis, R., His, E., Linden, M., Ormsby, A., Pettigrew, N., Rickert, R., Said, J., Bayer-Garner, I., Roche, P., Habegger-Vance, G., Brothman, A., Persons, D., Wilson, K., Mascarello, J., Roa, K., Herrmann, M., Cooley, L., Dewald, G., and Park, J. Use of tissue MIDI-arrays for HER2 quality assurance: A College of American Pathologists feasibility study. Unites States and Canadian Association of Pathology, Annual Meeting, February 2003.
44. Tawfik, O.W., Donahue, J.K, Fan, F., Davis, M., Persons, D.L., Connor, C., Jewell, W., Kimler, B.F. and Fabian, C.J. Comparison of immunohistochemistry (IHC) by automated cellular imaging system (ACIS) vs fluorescence in situ hybridization (FISH) in the evaluation of Her-2/*neu* expression in primary breast carcinoma. American Society of Clinical Oncology Meeting, May 2003.
45. V.K. Detection of gene copy number alterations using a panel of DNA FISH probes in malignant melanoma. American Association for Cancer Research Annual Meeting, July 2003.
46. Pan, X., Tang, Q, and Persons, D.L Mechanisms of curcumin-induced inhibition of cell growth and sensitization to cisplatin-mediated killing of ovarian cancer cells. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. November 2003.
47. Persons, D. L., Wang, X. Y., Collins, D., Arthur, T, Hagemester, S., Ragona, J., Davoren, B., Troyer, T., Schimke, R.N. Deletion of 22q11.2 associated with a jumping translocation. American Society of Human Genetics Annual Meeting, October 2004.
48. Marion, A. M., Rogan, P. K., Flejter, W., Persons, D., Cowan, J., and Knoll, J. Small upstream deletions of ABL are rare in chronic myelogenous leukemia. American Society of Human Genetics Annual Meeting, October 2004.
49. Tubbs, R.R, Hsi, H.D, Habegger-Vance, G., Roche, P. C., Brothman, A. R., Cooley, L. D., Linden, M.D., Pettigrew, N. M., Rickert, R. R., Said, J. W., Bayer-Garner, I. B., Nagle, R. B., Persons, D. L., Mascarello, J. T., Rao, K. W., Herrmann, M., Dewald, G., and Park, J. P. Cell Markers & Molecular Pathology Committee, College of American Pathologists, Chicago, Illinois, United States: Cytogenetics Committee, College of American Pathologists, Chicago, Illinois, United States and Cell Markers Committee, College of American Pathologists, Chicago, Illinois, United States. Immunohistochemistry and Fluorescence In Situ Hybridization Clinical Assays for HER2 Status in Breast Cancer: Paired Specimen Results from the Survey Programs of the College of American Pathologists (CAP). 27th Annual San Antonio Breast Cancer Symposium, December, 2004.
50. Arthur, T. Davoren, B., Hagemester, S., Ragona, J., Troyer T., Persons, D. Use of FISH to verify the presence of t(14;18) and t(11;14) in two distinct clones having different sex chromosome complements. Annual National AGT meeting, June, 2005.
51. Ragona, J., Hagemester, S., Arthur, T. Davoren, B., Troyer T., Meyer, J., Persons, D. Unusual mosaic karyotype in infant suspected of Down syndrome. Annual National AGT meeting, June, 2005.
52. Stasik, CJ, Ganguly, S., Hagemester, S, Cunningham, M, and Persons, DL. Infant Acute Lymphoblastic Leukemia with t(11;16)(q23;p13.3) and Lineage Switch into Acute Monoblastic Leukemia. College of American Pathologists Annual Meeting, September, 2005.

53. Dasouki M, Lushington G, Persons DL. Mapping of 2 new gene loci for Dandy-Walker Malformation. American Society of Human Genetics, Annual Meeting, Philadelphia, PA, 2008.

INVITED SEMINARS/WORKSHOPS

1. Application of Fluorescence *In situ* Hybridization to Solid Tumor Specimens. Workshop on fluorescence *in situ* hybridization. American Society of Clinical Pathology/ College of American Pathology Fall Meetings, October 1992.
2. *In situ* Hybridization Studies in Prostate Cancer and Topic #2 Tumor Cytogenetics. Workshop on Clinical Applications of Flow Cytometry, sponsored by Mayo Medical Laboratories, Jackson Hole, WY, September 1993.
3. Advances in Techniques of Fluorescence *In situ* Hybridization for Use in Solid Tumors. Vysis, Inc., Naperville, IL, January 1994.
4. Molecular Cytogenetics in Solid Tumors. Department of Pathology, Roswell Park Cancer Center, Buffalo, NY, June 1994.
5. Fluorescence *In situ* Hybridization as an Adjunct to Conventional Cytogenetics. Genetics seminar, University of Utah Medical Center, Salt Lake City, UT, June 1994.
6. The use of Molecular Cytogenetics in Hematologic Disorders. Division of Laboratory Medicine, M.D. Anderson Cancer Center, Houston, TX, May 1994.
7. Use of Fluorescence *In situ* Hybridization in Clinical Cytogenetics. Grand Rounds, Research Hospital, Kansas City, MO, March 1995.
8. Molecular Cytogenetic Studies in Ovarian Carcinoma. Southwest Oncology Group, Gyn Basic Science subcommittee, Rosemont, IL, October 1996.
9. Interphase Cytogenetics in Hematologic Disorders. Kansas City Pathology Society, November 1996.
10. Prenatal and Neonatal Cytogenetics. Neonatal Critical Care Update - Regional Workshop, University of Kansas Medical Center, January, 1997.
11. Clinical Cytogenetics. Human Genome Teacher Networking Project Workshop, Kansas City MO, May, 1997.
12. University of North Carolina Lineberger Comprehensive Cancer Center. Chapel Hill, North Carolina, September 1997. Collaborative consultation on: Amplification of HER-2/neu by fluorescent *In situ* hybridization (FISH): An alternate method to predict outcome following dose-escalated CAF in Stage II, node positive breast cancer patients. (Consultant for Vysis, Inc. and participant in multicenter study).
12. Genetic Markers in Cancer. Coffeerville Regional Medical Center Cancer Symposium, Coffeerville KS, October 1997.
13. Prenatal and Neonatal Cytogenetics. Neonatal Critical Care Update - Regional Workshop, Columbia Overland Park Regional Medical Center, November 1997.
14. Centre Hospitalier Universitaire De Nantes, Institut de Biologie, Nantes, France, February 1998. Collaborative consultation on: Amplification of HER-2/neu by fluorescent *in situ* hybridization (FISH): A case control study in patients with node negative invasive ductal breast carcinoma.

(Consultant for Vysis, Inc. and participant in multicenter study).

15. Clinical Relevance of HER-2/neu Amplification in Breast Cancer. Workshop on HER-2/neu detection and quantitation in breast cancer, 13th Annual Meeting of the Great Plains Genetics Service Network, Iowa City, Iowa, May 1998.
16. HER-2/neu: Role in Prognosis and Chemotherapeutic Resistance. Kansas Cancer Institute, Kansas City KS, June 1998.
17. FISH Based Assessment of HER-2 Amplification for Prognosis and Predictive Response to Therapy in Breast Cancer. Workshop on FISH Based Assessment of HER-2 Amplification, Sponsor - Vysis, Inc., 4th Annual Meeting, Association of Molecular Pathology, Crystal City, Virginia, Nov. 1998.
18. Food and Drug Administration, Pre-market approval application for a fluorescence *in situ* hybridization (FISH) assay used in the detection of amplification of the HER-2/neu gene from subjects with node positive, Stage II breast cancer. Invited participant for Vysis, Inc., FDA, Washington, DC, November 1998.
19. Advances in Cytogenetic Techniques for In-utero and Postnatal Evaluation. Perinatal Grand Rounds, Overland Park Medical Center, Kansas City, Kansas, December 1998.
20. Cytogenetics: Current Laboratory Techniques and Clinical Cases. Kansas Medical Education Foundation, Topeka, Kansas, February 1999.
21. Use of High Resolution and Molecular Cytogenetics in Pediatric Patients. Pediatric Grand Rounds, University of Kansas Medical Center, April 1999.
22. Modulation of Cisplatin Sensitivity in Lung Carcinoma. Experimental Therapeutics Program, Lawrence, KS, November 2000.
23. DNA Alterations in Cancer. CRA Plenary Session, Southwest Oncology Group Fall Meeting, Chicago IL, October 2001.
24. Regulation of cisplatin-induced p53 by ERK. Molecular and Integrated Physiology Seminar, University of Kansas Medical Center, March 2002.
25. Multicolor FISH for detection of recurrent bladder cancer in voided urine. Kansas City Pathology Society Meeting, September, 2002.
26. Update on Genetic Markers in Cancer. Coffeerville Regional Medical Center Cancer Symposium, Coffeerville KS, September 2002.
27. Exploring Health Initiatives in Research. Sponsored by the American Cancer Society, Overland Park, KS, November, 2002.
28. Cytogenetics and FISH in multiple myeloma. Southwest Oncology Group Cytogenetics Workshop. August, 2004, St. Louis, MO.
29. FISH: A cytogenetic or pathology test? 30th Annual AGT National Meeting, July 2005, Kansas City MO.
30. Inspecting the Cytogenetics and Molecular Laboratory. Workshop sponsored by the College of American Pathologists, at the Annual meeting of American College of Medical Genetics, San Diego, CA, March, 2006.

31. The CAP Laboratory Accreditation Process: Inspecting the Cytogenetics Laboratory. Workshop sponsored by the College of American Pathologists, at the Annual AGT National Meeting, Baltimore, Maryland, June, 2006.
32. Predictive Markers and FISH: Lessons Learned, Challenges Remaining. Mayo Clinic, Rochester MN, January 2007.
32. HER2 Gene Amplification in Breast Cancer. Concurrent Session: Gene Amplification in Neoplasia. Annual Meeting of the American College of Medical Genetics, March, 2007.
33. Inspecting the Cytogenetics and Molecular Laboratory. Workshop sponsored by the College of American Pathologists, at the Annual meeting of American College of Medical Genetics, San Diego, CA, March, 2008.

OTHER SCHORLARLY/SERVICE ACTIVITIES

Ad Hoc Journal Reviewer: American Journal of Clinical Pathology, American Journal of Pathology, Archives of Toxicology, Cancer, Cancer Chemotherapy and Pharmacology, Cancer Detection and Prevention, Cancer Genetics and Cytogenetics, Cancer Cytopathology, Cancer Research, Cell Death and Differentiation, Clinical Cancer Research, Experimental Cell Research, International Journal of Cancer, Journal of Biological Chemistry, Journal of Molecular Diagnostics, Mayo Clinic Proceedings, Melanoma Research, Oncogene, Southern Medical Journal, Toxicology and Applied Pharmacology.

Inspector, College of American Pathologists